In order to validate the therapeutic potential of the Ce-49 sh aptaDiR, we analyzed its function on cancer cell lines with different levels of DNMT1 protein including the myeloid leukaemia U937 cells and the non-small cell lung cancer Calu-1 and A549 cells characterized by low or intermediate DNMT1 levels, respectively, as compared to K562 that displays high DNMT1 levels (Supplementary Fig. 20). The gene discussed is DNMT1; the disease is myeloid leukemia.